For the quarter ending 2026-03-31, SXTP made $162,092 in revenue. -$2,089,214 in net income. Net profit margin of -1288.91%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product revenues net of discounts and rebates | 162,092 | 303,385 | 437,602 | 100,932 |
| Cost of revenues | 85,715 | 120,682 | 537,690 | 50,051 |
| Gross profit | 76,377 | 182,703 | -100,088 | 50,881 |
| Research revenues | 0 | 12,994 | 90,960 | 206,939 |
| Net revenue | 76,377 | 195,697 | -9,128 | 257,820 |
| Research and development | 281,464 | 638,873 | 809,777 | 249,884 |
| General and administrative expenses | 1,889,874 | 1,474,175 | 1,506,620 | 1,612,764 |
| Total operating expenses | 2,171,338 | 2,113,048 | 2,316,397 | 1,862,648 |
| Loss from operations | -2,094,961 | -1,917,351 | -2,325,525 | -1,604,828 |
| Interest expense | 1,389 | 3,086 | 1,708 | 1,221 |
| Change in fair value of derivative liabilities | 4,567 | 109,644 | 21,103 | 140,447 |
| Other income, net | 10,762 | 57,032 | 31,550 | 13,066 |
| Total interest and other income (expense), net | - | 476,480 | - | - |
| Total interest and other income, net | 4,806 | - | 8,739 | -128,602 |
| Loss from operations before provision for income taxes | -2,090,155 | -1,440,871 | -2,316,786 | -1,733,430 |
| Provision for income taxes (note 9) | 0 | -1,813 | 250 | 1,500 |
| Net loss | -2,090,155 | -1,439,058 | -2,317,036 | -1,734,930 |
| Net loss noncontrolling interest | -941 | -499 | -712 | -1,204 |
| Net loss attributed to 60 degrees pharmaceuticals, inc | -2,089,214 | -1,438,559 | -2,316,324 | -1,733,726 |
| Basic EPS | -1.28 | -1.955 | -0.66 | -1.25 |
| Diluted EPS | -1.28 | -1.955 | -0.66 | -1.25 |
| Basic Average Shares | 1,725,758 | 670,211* | 3,675,407 | 1,472,891 |
| Diluted Average Shares | 1,725,758 | 670,211* | 3,675,407 | 1,472,891 |
60 DEGREES PHARMACEUTICALS, INC. (SXTP)
60 DEGREES PHARMACEUTICALS, INC. (SXTP)